Hisashi Kosaka | Profiles RNS

Hisashi Kosaka, MD/PhD

Postdoctoral Fellow (previously held)

Boston University Chobanian & Avedisian School of Medicine

Anatomy & Neurobiology

Publications
Contact Info

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T. Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice. Cancer Med. 2026 Feb; 15(2):e71640. PMID: 41692425; PMCID: PMC12906954; DOI: 10.1002/cam4.71640;

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Tanaka H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Ueda Y, Kim SK, Tada F, Nakamura S, Matsuura T, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Okamura J, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T. Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study. Hepatol Res. 2026 Jan 09. PMID: 41511823

Shinkawa H, Ueda D, Kurimoto S, Kaibori M, Ueno M, Yasuda S, Ikoma H, Aihara T, Nakai T, Kinoshita M, Kosaka H, Hayami S, Matsuo Y, Morimura R, Nakajima T, Nobori C, Ishizawa T. Individualized Prognostication Based on Deep-Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection. Hepatol Res. 2026 Feb; 56(2):204-213. PMID: 41074716

Sumiyama F, Duong HH, Matsushima H, Matsui K, Yoshida T, Yamamoto H, Kosaka H, Sekimoto M, Nguyen VK, Lai TT, Ohigashi T, Akama TO, Yoshii K, Oe E, Fujisawa N, Ebara M, Kaibori M. Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials (Basel). 2025 Oct 05; 15(19). PMID: 41090868; PMCID: PMC12526398; DOI: 10.3390/nano15191524;

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Kanayama Y, Tada F, Nakamura S, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Tanaka H, Noritake H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab. Liver Int. 2025 Oct; 45(10):e70286. PMID: 40970650

Lai TT, Matsushima H, Kosaka H, Matsui K, Kiguchi G, Yamamoto H, Ohigashi T, Duong HH, Nguyen VK, Kariya S, Kaibori M. Management of retrohepatic inferior vena cava injury during hepatectomy and an intravascular foreign body caused by surgical gauze migration: a case report. J Surg Case Rep. 2025 Sep; 2025(9):rjaf755. PMID: 40979416; PMCID: PMC12449575; DOI: 10.1093/jscr/rjaf755;

Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Komatsu S, Tamai H, Okamura J, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Matsuura T, Noritake H, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T. Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis. Hepatol Res. 2026 Jan; 56(1):89-99. PMID: 40913797

Kosaka H, Ueno M, Shinkawa H, Yamamoto Y, Kinoshita M, Komeda K, Aihara T, Yasuda S, Mori H, Kaibori M. Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage-Stratified Analysis. Ann Gastroenterol Surg. 2026 Jan; 10(1):241-250. PMID: 41488852; PMCID: PMC12757147; DOI: 10.1002/ags3.70087;

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T. Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma. J Gastroenterol. 2025 Nov; 60(11):1427-1436. PMID: 40833596

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Kanayama Y, Tanaka K, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Miyake T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, Kudo M, Hiasa Y, Kumada T. Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma. Oncology. 2025 Aug 08; 1-10. PMID: 40784334

Showing 10 of 131 results. Show More

Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Noritake H, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Matsui K, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M. Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. Hepatol Res. 2025 Nov; 55(11):1507-1517. PMID: 40767262

Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Matsui K, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M. Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab. Liver Int. 2025 Aug; 45(8):e70217. PMID: 40622190

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Ohama H, Kanayama Y, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, Kudo M, Hiasa Y, Kumada T. Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma. Liver Cancer. 2025 Jul 21. PMID: 41063740; PMCID: PMC12503761; DOI: 10.1159/000547519;

Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study. Liver Int. 2025 Jul; 45(7):e70192. PMID: 40558097

Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M. Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Hepatol Res. 2025 Sep; 55(9):1285-1295. PMID: 40515751

Tanaka S, Noda T, Komeda K, Yasuda S, Ueno M, Mori H, Kosaka H, Morimura R, Shinkawa H, Sekiguchi N, Ikoma H, Ishizawa T, Kaibori M. Risk for Recurrence After Liver Resection in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Detected After Sustained Virological Response by Direct-Acting Antivirals: A Retrospective Multicenter Study. Cancers (Basel). 2025 Jun 11; 17(12). PMID: 40563597; PMCID: PMC12191199; DOI: 10.3390/cancers17121946;

Kosaka H, Ikezoe T, Hase K, Kimura Y, Miyauchi T, Lai TT, Van Nguyen K, Inoue K, Takada M, Matsushima H, Kiguchi G, Yamamoto H, Matsui K, Taketani M, Shirai T, Kaibori M. Pilot Study to Assess the Ability of a 4-Week, Home-Based, Electrical Muscle Stimulation Program to Improve Lower Extremity Function and Reduce Sarcopenia in Older Individuals With Cancer. Arch Rehabil Res Clin Transl. 2025 Sep; 7(3):100479. PMID: 40980522; PMCID: PMC12447214; DOI: 10.1016/j.arrct.2025.100479;

Toyoda H, Hiraoka A, Ochi H, Tsuji K, Tajiri K, Tani J, Tada T, Okubo T, Atsukawa M, Hirooka M, Itobayashi E, Hatanaka T, Kariyama K, Ishikawa T, Kuroda H, Takaguchi K, Kosaka H, Kawada K, Kakizaki S, Yada Y, Ogawa C, Nishimura T, Yasuda S, Deguchi A, Morishita A, Itokawa N, Arai T, Tsutsui A, Naganuma A, Enomoto H, Kaibori M, Nouso K, Hiasa Y, Kumada T, Akita T, Tanaka J, Johnson PJ. Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival Benefit. JCO Clin Cancer Inform. 2025 May; 9:e2400175. PMID: 40354590

Nguyen KV, Matsui K, Kosaka H, Matsushima H, Yamamoto H, Lai TT, Inoue K, Takada M, Tada F, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kato H, Yoshii K, Yamaguchi T, Shimoda S, Naganuma M, Kaibori M. Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy. Oncology. 2026; 104(2):113-124. PMID: 40159321

Nakamura N, Matsuno Y, Aoi K, Kosaka H, Kobayashi S, Takahashi Y, Tahara T, Noda Y, Tsuta K, Naganuma M. Hepatic Sarcoidosis Mimicking a Metastatic Tumor. Intern Med. 2025 Aug 15; 64(16):2439-2445. PMID: 39971299; PMCID: PMC12425587; DOI: 10.2169/internalmedicine.4528-24;

Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. Hepatol Res. 2025 May; 55(5):741-751. PMID: 40317628

Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Toyoda H, Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouso K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T. The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient. Oncology. 2026; 104(1):79-91. PMID: 39900019

Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M. Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC. J Gastroenterol Hepatol. 2025 Apr; 40(4):949-959. PMID: 39844393

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T. Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models. J Gastroenterol Hepatol. 2025 Apr; 40(4):930-939. PMID: 39762722

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Tanaka H, Nishikawa H, Shibata H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib. Sci Rep. 2025 Jan 02; 15(1):72. PMID: 39747852; PMCID: PMC11696502; DOI: 10.1038/s41598-024-78539-4;

Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma. Cancer Med. 2025 Jan; 14(2):e70618. PMID: 39840727; PMCID: PMC11751879; DOI: 10.1002/cam4.70618;

Kinoshita M, Kosaka H, Kaibori M, Ueno M, Yasuda S, Komeda K, Yamamoto Y, Tani M, Aihara T, Shinkawa H, Hayami S, Matsuo Y, Kawaguchi N, Morimura R, Mori H, Nakajima T, Kubo S, Ishizawa T. Favorable impact of hepatitis C virus infection control on recurrence after surgical resection for intrahepatic cholangiocarcinoma. Hepatol Res. 2025 May; 55(5):707-717. PMID: 40317596

Lai TT, Ishida M, Kosaka H, Matsui K, Matsushima H, Yamamoto H, Kiguchi G, Nguyen KV, Inoue K, Takada M, Kato H, Hirose Y, Yoshii K, Kaibori M. The Prognostic Impact of Adipophilin Expression on Long-Term Survival Following Liver Resection in Patients with Colorectal Liver Metastases. Cancers (Basel). 2024 Nov 14; 16(22). PMID: 39594782; PMCID: PMC11592894; DOI: 10.3390/cancers16223827;

Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice. Hepatol Res. 2025 Mar; 55(3):444-453. PMID: 39526824

Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study. Oncology. 2025; 103(6):456-468. PMID: 39396495

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients. Aliment Pharmacol Ther. 2024 Nov; 60(10):1361-1373. PMID: 39233317

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. J Clin Oncol. 2024 Dec; 42(34):4060-4070. PMID: 39197119; PMCID: PMC11608592; DOI: 10.1200/JCO.24.00645;

Shinkawa H, Kaibori M, Ueno M, Yasuda S, Ikoma H, Aihara T, Nakai T, Kinoshita M, Kosaka H, Hayami S, Matsuo Y, Morimura R, Nakajima T, Nobori C, Ishizawa T. Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study. Liver Cancer. 2025 Mar; 14(1):80-91. PMID: 40144468; PMCID: PMC11936440; DOI: 10.1159/000540858;

Kosaka H, Matsui K, Ikeura T, Ito T, Ohe C, Kono Y, Matsushima H, Yamamoto H, Sekimoto M, Kaibori M. Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers. Surg Today. 2025 Mar; 55(3):351-359. PMID: 39136750

Promsorn P, Yamaguchi T, Kosaka H, Aoi K, Yoshida K, Matsushima H, Matsui K, Shimoda S, Kaibori M, Naganuma M. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib. Mol Clin Oncol. 2024 Sep; 21(3):63. PMID: 39071976; PMCID: PMC11273243; DOI: 10.3892/mco.2024.2761;

Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T. Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study. Cancer Immunol Immunother. 2024 May 11; 73(7):126. PMID: 38733406; PMCID: PMC11088591; DOI: 10.1007/s00262-024-03707-4;

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. Aliment Pharmacol Ther. 2024 Jul; 60(2):233-245. PMID: 38716823

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Target Oncol. 2024 Jul; 19(4):645-659. PMID: 38689194; PMCID: PMC11230956; DOI: 10.1007/s11523-024-01061-0;

Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. Liver Cancer. 2024 Oct; 13(5):522-536. PMID: 39296620; PMCID: PMC11407762; DOI: 10.1159/000537915;

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, Toyoda H, Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma. Cancer Rep (Hoboken). 2024 Apr; 7(4):e2042. PMID: 38577725; PMCID: PMC10995717; DOI: 10.1002/cnr2.2042;

Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab. Liver Int. 2024 May; 44(5):1108-1125. PMID: 38517286

Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma. Target Oncol. 2024 Jan; 19(1):29-39. PMID: 38252195

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study. Hepatol Res. 2024 Apr; 54(4):382-391. PMID: 37983642

Shinkawa H, Kaibori M, Kabata D, Nakai T, Ueno M, Hokuto D, Ikoma H, Iida H, Komeda K, Tanaka S, Kosaka H, Nobori C, Hayami S, Yasuda S, Morimura R, Mori H, Kagota S, Kubo S, Ishizawa T. Laparoscopic and open minor liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a multicenter study using inverse probability weighting approach. Surg Endosc. 2024 Feb; 38(2):757-768. PMID: 38052887

Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. a-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Int J Cancer. 2024 Mar 15; 154(6):1043-1056. PMID: 37994647

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T. Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach. Cancer Med. 2023 Dec; 12(24):21680-21693. PMID: 37987139; PMCID: PMC10757119; DOI: 10.1002/cam4.6726;

Kosaka H, Ishida M, Ueno M, Komeda K, Yasuda S, Mori H, Matsui K, Hirose Y, Sekimoto M, Kaibori M. Impact of Trinal Histological Glandular Differentiation Grade on the Prognosis of Patients with Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Study. J Gastrointest Surg. 2023 Dec; 27(12):2780-2786. PMID: 37884751

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma. Liver Int. 2024 Jan; 44(1):113-124. PMID: 37789669

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers (Basel). 2023 Aug 31; 15(17). PMID: 37686624; PMCID: PMC10486534; DOI: 10.3390/cancers15174348;

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings. Oncology. 2023; 101(9):542-552. PMID: 37552968

Tada F, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices. J Gastroenterol. 2023 Nov; 58(11):1134-1143. PMID: 37528255

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y. Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatol Res. 2023 Oct; 53(10):1031-1042. PMID: 37306040

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function. Oncology. 2023; 101(10):624-633. PMID: 37307798

Ueno M, Kosaka H, Iida H, Ida Y, Aoi K, Mori H, Miyamoto A, Nishida Y, Hayami S, Kawai M, Kaibori M. Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study. Oncology. 2023; 101(9):565-574. PMID: 37276856

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Soldà C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023 Aug; 189:112933. PMID: 37385069

Okuyama A, Kosaka H, Kaibori M, Higashi T, Ogawa A. Activities of daily living after surgery among older patients with gastrointestinal and hepatobiliary-pancreatic cancers: a retrospective observational study using nationwide health services utilisation data from Japan. BMJ Open. 2023 May 25; 13(5):e070415. PMID: 37230526; PMCID: PMC10230979; DOI: 10.1136/bmjopen-2022-070415;

Kaibori M, Yoshii K, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Nakajima T, Aoi K, Yamaguchi T, Yoshida K, Sekimoto M. The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy. Cancers (Basel). 2023 May 25; 15(11). PMID: 37296868; PMCID: PMC10251914; DOI: 10.3390/cancers15112905;

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2023 Aug; 38(8):1389-1397. PMID: 37231943

Ota M, Komeda K, Iida HO, Ueno M, Kosaka H, Nomi T, Tanaka S, Nakai T, Hokutou D, Matsumoto M, Hirokawa F, Lee SW, Kaibori M, Kubo S. ASO Visual Abstract: The Prognostic Value of Preoperative Serum Markers and Risk Classification for Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2023 May; 30(5):2818-2819. PMID: 36622526

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Tanaka T, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T. Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis. Hepatol Res. 2023 Aug; 53(8):737-748. PMID: 37020416

Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023 Aug; 149(10):7565-7577. PMID: 36976353; PMCID: PMC11798051; DOI: 10.1007/s00432-023-04678-2;

Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Target Oncol. 2023 Mar; 18(2):221-233. PMID: 36920648

Yamamoto H, Kaibori M, Matsushima H, Kosaka H, Matsui K, Sekimoto M. Efficacy and Safety of Liver Resection in Super Elderly Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2023 Mar 01; 24(3):1089-1094. PMID: 36974565; PMCID: PMC10334108; DOI: 10.31557/APJCP.2023.24.3.1089;

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Oncology. 2023; 101(5):283-291. PMID: 36657420

Ota M, Komeda K, Iida H, Ueno M, Kosaka H, Nomi T, Tanaka S, Nakai T, Hokutou D, Matsumoto M, Hirokawa F, Lee SW, Kaibori M, Kubo S. The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2023 May; 30(5):2807-2815. PMID: 36641514

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023 Apr; 12(7):7772-7783. PMID: 36518086; PMCID: PMC10134356; DOI: 10.1002/cam4.5535;

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. J Cancer Res Clin Oncol. 2023 Aug; 149(9):5591-5602. PMID: 36509984; PMCID: PMC11798241; DOI: 10.1007/s00432-022-04512-1;

Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Med. 2023 Mar; 12(6):6980-6993. PMID: 36484470; PMCID: PMC10067064; DOI: 10.1002/cam4.5495;

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kaibori M, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kosaka H, Hiasa Y, Kudo M. Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis. Liver Cancer. 2023 Aug; 12(3):209-217. PMID: 37601983; PMCID: PMC10433099; DOI: 10.1159/000527402;

Tanaka S, Noda T, Komeda K, Kosaka H, Iida H, Ueno M, Hokuto D, Ikoma H, Nakai T, Kabata D, Shinkawa H, Kobayashi S, Hirokawa F, Mori H, Hayami S, Morimura R, Matsumoto M, Ishizawa T, Kubo S, Kaibori M. Surgical Outcomes for Hepatocellular Carcinoma in Patients with Child-Pugh Class B: a Retrospective Multicenter Study. J Gastrointest Surg. 2023 Feb; 27(2):283-295. PMID: 36471191

Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y. Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Oncology. 2023; 101(4):270-282. PMID: 36455517

Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023 Feb; 180:9-20. PMID: 36527976

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T. Correction to: Development and validation of a modified albumin-bilirubin grade and a-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab. Hepatol Int. 2023 Feb; 17(1):271-273. PMID: 36385371

Kaibori M, Yoshii K, Kosaka H, Ota M, Komeda K, Ueno M, Hokutou D, Iida H, Matsui K, Sekimoto M. Preoperative Serum Markers and Risk Classification in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study. Cancers (Basel). 2022 Nov 07; 14(21). PMID: 36358877; PMCID: PMC9658667; DOI: 10.3390/cancers14215459;

Kaibori M, Yoshii K, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Aoi K, Yamaguchi T, Yoshida K, Hatanaka T, Hiraoka A, Tada T, Kumada T, Sekimoto M. Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy. Cancers (Basel). 2022 Oct 27; 14(21). PMID: 36358711; PMCID: PMC9655685; DOI: 10.3390/cancers14215292;

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 2023 Mar; 12(5):5293-5303. PMID: 36226511; PMCID: PMC10028018; DOI: 10.1002/cam4.5337;

Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis. Cancer Med. 2023 Feb; 12(4):4259-4269. PMID: 36156452; PMCID: PMC9972107; DOI: 10.1002/cam4.5294;

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M. Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma. Oncology. 2022; 100(12):645-654. PMID: 36103846

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T. Development and validation of a modified albumin-bilirubin grade and a-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab. Hepatol Int. 2023 Feb; 17(1):86-96. PMID: 36076009

Kosaka H, Ishida M, Ueno M, Komeda K, Hokutou D, Iida H, Hirokawa F, Matsui K, Sekimoto M, Kaibori M. Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study. Ann Gastroenterol Surg. 2023 Jan; 7(1):138-146. PMID: 36643363; PMCID: PMC9831894; DOI: 10.1002/ags3.12605;

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int. 2022 Oct; 16(5):1150-1160. PMID: 35749019

Okamoto Y, Ishizuka M, Sumiyama F, Kosaka H, Suganami A, Tamura Y, Sekimoto M, Kaibori M. Inhibitory effects and gene expression analysis of chemotherapeutic photodynamic therapy by using a liposomally formulated indocyanine green derivative. Photodiagnosis Photodyn Ther. 2022 Sep; 39:102961. PMID: 35700912

Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022 Sep; 52(9):773-783. PMID: 35633504

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib. Cancer Med. 2023 Jan; 12(1):325-334. PMID: 35666040; PMCID: PMC9844603; DOI: 10.1002/cam4.4854;

Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, Toyoda H, Yasuda S, Naganuma A, Tada T, Takaguchi K, Tsutsui A, Itobayashi E, Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouso K, Kosaka H, Kaibori M, Kumada T. The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan. Cancer Med. 2023 Jan; 12(1):345-357. PMID: 35608226; PMCID: PMC9844645; DOI: 10.1002/cam4.4850;

Kaibori M, Hiraoka A, Iida H, Komeda K, Hirokawa F, Ueno M, Kosaka H, Matsui K, Sekimoto M. Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan. Cancers (Basel). 2022 Apr 22; 14(9). PMID: 35565221; PMCID: PMC9105166; DOI: 10.3390/cancers14092091;

Yoshida T, Kaibori M, Fujisawa N, Ishizuka M, Sumiyama F, Hatta M, Kosaka H, Matsui K, Suzuki K, Akama TO, Katano T, Yoshii K, Ebara M, Sekimoto M. Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model. Nanomaterials (Basel). 2022 Apr 15; 12(8). PMID: 35458072; PMCID: PMC9025678; DOI: 10.3390/nano12081364;

Matsushima H, Ishizaki M, Kosaka H, Matsui K, Sekimoto M, Kaibori M. A case of undifferentiated carcinoma of the gallbladder with severe inflammation and difficult preoperative chemotherapy. Clin J Gastroenterol. 2022 Jun; 15(3):623-629. PMID: 35304706

Kaibori M, Hiraoka A, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Yamaguchi T, Yoshida K, Sekimoto M. Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases. Cancers (Basel). 2022 Mar 09; 14(6). PMID: 35326554; PMCID: PMC8946274; DOI: 10.3390/cancers14061402;

Kosaka H, Ueno M, Komeda K, Hokuto D, Iida H, Hirokawa F, Matsui K, Sekimoto M, Kaibori M. The Impact of a Preoperative Staging System on Accurate Prediction of Prognosis in Intrahepatic Cholangiocarcinoma. Cancers (Basel). 2022 Feb 22; 14(5). PMID: 35267414; PMCID: PMC8909481; DOI: 10.3390/cancers14051107;

Shinkawa H, Hirokawa F, Kaibori M, Nomi T, Ueno M, Ikoma H, Nakai T, Iida H, Tanaka S, Komeda K, Kosaka H, Hokuto D, Hayami S, Morimura R, Matsumoto M, Maehira H, Takemura S, Kubo S. Risk factors for and management of morbidity in pure laparoscopic resection of the right posterosuperior segments of the liver: A multicenter retrospective study. Asian J Endosc Surg. 2022 Jul; 15(3):539-546. PMID: 35170224

Ueno M, Iida H, Komeda K, Kosaka H, Hirokawa F, Hayami S, Mori H, Kaibori M, Yamaue H. Dorsal vs ventral approach to the middle hepatic vein during laparoscopic left hemihepatectomy: multicenter retrospective observational study. Surg Endosc. 2022 Sep; 36(9):6464-6472. PMID: 35024938

Kaibori M, Sakai K, Matsushima H, Kosaka H, Matsui K, De Velasco MA, Sekimoto M, Nishio K. Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. Hepatol Int. 2022 Feb; 16(1):135-147. PMID: 34973129; PMCID: PMC8843910; DOI: 10.1007/s12072-021-10278-4;

Shinkawa H, Hirokawa F, Kaibori M, Kabata D, Nomi T, Ueno M, Ikoma H, Nakai T, Iida H, Tanaka S, Komeda K, Kosaka H, Hokuto D, Hayami S, Morimura R, Matsumoto M, Maehira H, Takemura S, Kubo S. Impact of laparoscopic parenchyma-sparing resection of lesions in the right posterosuperior liver segments on surgical outcomes: A multicenter study based on propensity score analysis. Surgery. 2022 May; 171(5):1311-1319. PMID: 34887090

Kaibori M, Matsushima H, Matsui K, Kosaka H, Yamamoto H, Yoshii K, Sekimoto M. Prospective Study to Evaluate the Safety and Efficacy of a New Surgical Tube Fixation Method: A Pilot Study. World J Surg. 2022 03; 46(3):542-549. PMID: 34773134

Hirokawa F, Ueno M, Nakai T, Kaibori M, Nomi T, Iida H, Tanaka S, Komeda K, Hayami S, Kosaka H, Hokuto D, Kubo S, Uchiyama K. Treatment strategy for resectable colorectal cancer liver metastases from the viewpoint of time to surgical failure. Langenbecks Arch Surg. 2022 Mar; 407(2):699-706. PMID: 34741671

Kosaka H, Satoi S, Kono Y, Yamamoto T, Hirooka S, Yamaki S, Hashimoto D, Sakaguchi T, Sekimoto M. Estimation of the degree of surgical difficulty anticipated for pancreatoduodenectomy: Preoperative and intraoperative factors. J Hepatobiliary Pancreat Sci. 2022 Nov; 29(11):1166-1174. PMID: 34596977

Kaibori M, Kosaka H. Effect of hydrogen gas inhalation on patient QOL after hepatectomy: protocol for a randomized controlled trial. Trials. 2021 Oct 21; 22(1):727. PMID: 34674744; PMCID: PMC8529823; DOI: 10.1186/s13063-021-05697-5;

Hirokawa F, Ueno M, Nakai T, Kaibori M, Nomi T, Iida H, Tanaka S, Komeda K, Hayami S, Kosaka H, Hokuto D, Kubo S, Uchiyama K. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study. J Gastrointest Surg. 2022 Apr; 26(4):772-781. PMID: 34664190

Kosaka H, Kaibori M, Chu DI, Stucchi AF, Sekimoto M. Role of Substance P-Dependent Chemotactic Signaling in Postoperative Adhesion Formation. J Surg Res. 2022 02; 270:49-57. PMID: 34638093

Ueno M, Komeda K, Kosaka H, Nakai T, Nomi T, Iida H, Tanaka S, Ikoma H, Matsuda K, Hirokawa F, Matsumoto M, Hokuto D, Mori H, Morimura R, Kaibori M, Yamaue H, Kubo S. Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study. Int J Surg. 2021 Oct; 94:106106. PMID: 34536602

Ishizaki M, Kaibori M, Matsushima H, Kosaka H, Matsui K, Sekimoto M. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma. Clin J Gastroenterol. 2021 Dec; 14(6):1700-1705. PMID: 34480729

Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Nakatani M, Kariya S, Yamaguchi T, Yoshida K, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion. Cancer Invest. 2022 Jan; 40(1):81-89. PMID: 34236269

Ryota H, Ishida M, Ebisu Y, Yanagimoto H, Yamamoto T, Kosaka H, Hirooka S, Yamaki S, Kotsuka M, Matsui Y, Tsuta K, Satoi S. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC? immunostaining for detection of reverse polarity. Oncol Lett. 2021 Jul; 22(1):525. PMID: 34055090; PMCID: PMC8138900; DOI: 10.3892/ol.2021.12786;

Kosaka H, Kaibori M, Matsui K, Ishizaki M, Matsushima H, Sekimoto M. Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. Asian Pac J Cancer Prev. 2021 May 01; 22(5):1485-1493. PMID: 34048177; PMCID: PMC8408380; DOI: 10.31557/APJCP.2021.22.5.1485;

Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2021 Apr 01; 22(4):1217-1224. PMID: 33906315; PMCID: PMC8325117; DOI: 10.31557/APJCP.2021.22.4.1217;

Kaibori M, Kosaka H, Matsui K, Ishizaki M, Matsushima H, Tsuda T, Hishikawa H, Okumura T, Sekimoto M. Near-Infrared Fluorescence Imaging and Photodynamic Therapy for Liver Tumors. Front Oncol. 2021; 11:638327. PMID: 33718233; PMCID: PMC7947679; DOI: 10.3389/fonc.2021.638327;

Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Ogawa A, Yoshii K, Sekimoto M. Perioperative Geriatric Assessment as A Predictor of Long-Term Hepatectomy Outcomes in Elderly Patients with Hepatocellular Carcinoma. Cancers (Basel). 2021 Feb 17; 13(4). PMID: 33671388; PMCID: PMC7922697; DOI: 10.3390/cancers13040842;

Kosaka H, Kaibori M, Kariya S, Ueno Y, Matsui K, Yamamoto H, Matsushima H, Hamamoto T, Sekimoto M. The percutaneous tandem drainage technique for radical treatment of intractable hepaticojejunostomy leakage. Drug Discov Ther. 2021; 15(3):169-170. PMID: 34234068

Nakamura K, Sho M, Satoi S, Kosaka H, Akahori T, Nagai M, Nakagawa K, Takagi T, Yamamoto T, Yamaki S. Impact of Antithrombotic Agents on Postpancreatectomy Hemorrhage: Results from a Retrospective Multicenter Study. J Am Coll Surg. 2020 10; 231(4):460-469.e1. PMID: 32634474

Matsui Y, Hirooka S, Sakaguchi T, Kotsuka M, Yamaki S, Yamamoto T, Kosaka H, Satoi S, Sekimoto M. Bile Duct Stones Predict a Requirement for Cholecystectomy in Older Patients. World J Surg. 2020 03; 44(3):721-729. PMID: 31654201

Kosaka H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Sakaguchi T, Inoue K, Matsui Y, Sekimoto M. Clinical impact of the sequentially-checked drain removal criteria on postoperative outcomes after pancreatectomy: a retrospective study. J Hepatobiliary Pancreat Sci. 2019 Sep; 26(9):426-434. PMID: 31237409

Matsui Y, Hirooka S, Kotsuka M, Yamaki S, Kosaka H, Yamamoto T, Satoi S. Prognosis in Patients With Gallbladder Edema Misdiagnosed as Cholecystitis. JSLS. 2019 Apr-Jun; 23(2). PMID: 31223228; PMCID: PMC6573792; DOI: 10.4293/JSLS.2019.00022;

Hashimoto Y, Ishida M, Ryota H, Yamamoto T, Kosaka H, Hirooka S, Yamaki S, Kotsuka M, Matsui Y, Yanagimoto H, Tsuta K, Satoi S. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Pancreatology. 2019 Apr; 19(3):443-448. PMID: 30879968

Ryota H, Ishida M, Satoi S, Yanagimoto H, Yamamoto T, Kosaka H, Hirooka S, Yamaki S, Kotsuka M, Matsui Y, Ikeura T, Uchida K, Takaoka M, Okazaki K, Tsuta K. Clinicopathological and immunological features of follicular pancreatitis - a distinct disease entity characterised by Th17 activation. Histopathology. 2019 Apr; 74(5):709-717. PMID: 30515871

Matsui Y, Hirooka S, Yamaki S, Kotsuka M, Kosaka H, Yamamoto T, Satoi S. Assessment of clinical outcome of cholecystectomy according to age in preparation for the "Silver Tsunami". Am J Surg. 2019 09; 218(3):567-570. PMID: 30728100

Yamamoto T, Satoi S, Fujii T, Yamada S, Yanagimoto H, Yamaki S, Takami H, Hirooka S, Kosaka H, Kotsuka M, Miyara T, Kodera Y. Dual-center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage. Ann Gastroenterol Surg. 2018 Nov; 2(6):442-450. PMID: 30460348; PMCID: PMC6236101; DOI: 10.1002/ags3.12209;

Satoi S, Yamamoto T, Yanagimoto H, Yamaki S, Kosaka H, Hirooka S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y. Does modified Blumgart anastomosis without intra-pancreatic ductal stenting reduce post-operative pancreatic fistula after pancreaticojejunostomy? Asian J Surg. 2019 Jan; 42(1):343-349. PMID: 30087009

Matsui Y, Hirooka S, Kotsuka M, Yamaki S, Yamamoto T, Kosaka H, Satoi S. Use of a piece of free omentum to prevent bile leakage after subtotal cholecystectomy. Surgery. 2018 09; 164(3):419-423. PMID: 29887421

Matsui Y, Satoi S, Hirooka S, Kosaka H, Kawaura T, Kitawaki T. Reappraisal of previously reported meta-analyses on antibiotic prophylaxis for low-risk laparoscopic cholecystectomy: an overview of systematic reviews. BMJ Open. 2018 03 16; 8(3):e016666. PMID: 29549197; PMCID: PMC5857705; DOI: 10.1136/bmjopen-2017-016666;

Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Hashimoto Y, Matsui Y, Kon M. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. J Hepatobiliary Pancreat Sci. 2017 May; 24(5):289-296. PMID: 28301088; DOI: 10.1002/jhbp.447;

Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Yamaki S, Kosaka H, Hirooka S, Kotsuka M, Michiura T, Inoue K, Matsui Y, Kon M. Comparison of surgical outcomes of three different stump closure techniques during distal pancreatectomy. Pancreatology. 2017 May - Jun; 17(3):497-503. PMID: 28411019; DOI: 10.1016/j.pan.2017.04.005;

Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Matsui Y, Kon M. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Dec; 23(12):750-755. PMID: 27794194; DOI: 10.1002/jhbp.408;

Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Kotsuka M, Inoue K, Matsui Y, Kon M. Acute median arcuate ligament syndrome after pancreaticoduodenectomy. Surg Case Rep. 2016 Dec; 2(1):113. PMID: 27744644; PMCID: PMC5065883; DOI: 10.1186/s40792-016-0242-6;

Suzumura K, Kuroda N, Kosaka H, Iimuro Y, Hirano T, Fujimoto J. Delayed arterial hemorrhage after pancreaticoduodenectomy. Int Surg. 2014 Jul-Aug; 99(4):432-7. PMID: 25058779; PMCID: PMC4114375; DOI: 10.9738/INTSURG-D-13-00085.1;

Cassidy MR, Sheldon HK, Gainsbury ML, Gillespie E, Kosaka H, Heydrick S, Stucchi AF. The neurokinin 1 receptor regulates peritoneal fibrinolytic activity and postoperative adhesion formation. J Surg Res. 2014 Sep; 191(1):12-8.View Related Profiles.

Kosaka, Hisashi
Cassidy, Michael
Heydrick, Stanley

PMID: 24836694; DOI: 10.1016/j.jss.2014.04.030;

Kosaka H, Kuroda N, Suzumura K, Asano Y, Okada T, Fujimoto J. Multivariate logistic regression analysis for prediction of clinically relevant pancreatic fistula in the early phase after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2014 Feb; 21(2):128-33. PMID: 23804410; DOI: 10.1002/jhbp.11;

Kosaka H, Yoshimoto T, Yoshimoto T, Fujimoto J, Nakanishi K. Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med. 2008 Apr; 14(4):437-41. PMID: 18345012; DOI: 10.1038/nm1733;

Yamanaka J, Iimuro Y, Hirano T, Kosaka H, Fujimoto J. Successful liver resection for biliary atresia with intrahepatic biliary cysts after Kasai procedure. J Pediatr Surg. 2005 Feb; 40(2):E9-11. PMID: 15750917

Matsusaka S, Yamasaki H, Kitayama Y, Okada T, Maeda S, Dan T, Kosaka H, Tanabe H. [A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy]. Gan To Kagaku Ryoho. 2002 May; 29(5):777-9. PMID: 12040684

Matsusaka S, Oriyama T, Okada T, Chang W, Maeda S, Kondo Y, Kosaka H. [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy]. Gan To Kagaku Ryoho. 2002 Mar; 29(3):461-4. PMID: 11915740

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 131 publications over 16 distinct years, with a maximum of 28 publications in 2022

Bar chart showing 131 publications over 16 distinct years, with a maximum of 28 publications in 2022

Year	Publications
2002	2
2005	1
2008	1
2013	1
2014	2
2016	2
2017	2
2018	4
2019	5
2020	2
2021	16
2022	28
2023	23
2024	16
2025	24
2026	2

Contact for Mentoring:

Download vCard

Kosaka's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (255) concept(s)

Co-Authors

Heydrick, Stanley

See all (1) people

Similar People

See all (60) people

Same Department

Search Department